Summary
42 / 100 · Bulios Score
What speaks for it
- The share price is below the Bulios Fair Price.
- Out of every 100 USD of revenue, 24 USD is left as free cash.
- It bought back its own shares for $148.3M in the last fiscal year, 10% of its market value.
What to watch
- Earnings per share fell by 22% a year over the last 3 years.
- Out of every 100 USD of revenue, only 2.0 USD is left as net profit.
- It earns only 1.4 USD a year on every 100 USD of invested capital.
- Operating profit covers the interest on its debt only 2.1 times.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks cheapBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 99.0 USD for 1 USD of yearly profit. Over the last five years it was 96.5 USD on average.
Valuation in detailIs it growing?
It is shrinkingRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 11% a year over 5 years. Over the last 3 years it grew by 2.9% a year. For the next fiscal year analysts expect revenue to grow by 3.8%. Earnings per share fell by 22% a year over the last 3 years.
Growth in detailDoes it make money?
ReasonablyWhere 100 USD of revenue goes
- Cost of sales 21 USD
- Research and development 16 USD
- Sales and administration 60 USD
- Taxes and other 0.5 USD
- Net profit 2.0 USD
Net profit, industry median (Drug Manufacturers - Specialty & Generic) 10 USD
Out of every 100 USD of revenue, 2.0 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.3 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Neutral- Buy 11
- Hold 22
- Sell 3
Today's price within the analysts' price targets
The average target of $29.4 is 19% below today's price. 31% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Product 51%
- EXPAREL 40%
- ZILRETTA 8.2%
- Bupivacaine Liposome Injectable Suspension 0.5%
By region
The company reports no revenue by region.
Product brings in 51% of revenue. ZILRETTA grew fastest, by 74% a year.
Segments in detail